Company Information

  

Address: 540-1385 WEST 8TH AVENUE  
City: Vancouver 
State:  
Zip Code: V6H 3V9 
Telephone: (604) 678-1388 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Zymeworks is an innovative, clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Our suite of complementary therapeutic platforms and our fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated product candidates. These capabilities have resulted in multiple wholly owned product candidates with the potential to drive superior outcomes in large underserved and unaddressed patient populations, as further described below. Our lead product candidate, ZW25, is a novel bispecific (dual-targeting) antibody which targets two distinct domains of the human epidermal growth factor receptor 2, or HER2.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/20180.06NA246.33
03/2018-0.22NAN/E
12/2017-0.64NAN/E
09/2017-0.53NAN/E
06/2017-0.90NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.04Total Liab/Total Assets0.12
Net Inc/Total Assets-0.08Total Liab/Inv Cap0.13
Net Inc/Inv Cap-0.09Total Liab/Comm Equity0.07
Pretax Inc/Net Sales-0.19Interest Coverage Ratio-10.17
Net Inc/Net Sales-0.20Curr Debt/EquityNA
Cash Flow/Net Sales0.00LTD/EquityNA
SG&A/NetSales0.34Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover15.60Quick Ratio6.30
Inventory TurnoverNACurrent Ratio6.30
Inventory Day SalesNANet Rec/Curr Assets0.03
Net Sales/Work Cap0.67Inv/Curr AssetsNA
Net Sales/PP&E7.21  

Income Statement (Millions)

  6/30/2018 3/31/2018
Total Revenues(Net Sales) 22.00 0.04
Cost of Goods Sold NA NA
Selling & Admin Exps 8.65 7.07
Operating Income -2.02 -20.11
Interest Exp 0.01 0.01
Pretax Income -4.03 -21.27
Other Income -2.01 -1.15
Net Income Bef Extraordinary ... NA NA
Net Income -5.87 -21.20

Balance Sheet (Millions)

Assets 6/30/2018 3/31/2018
Cash & Short Term Investments 166.23 70.03
Receivables - Total 2.23 1.98
Inventories - Total NA NA
Total Current Assets 172.26 74.42
Net Property, Plant & Equipment 6.75 6.95
Total Assets 211.00 113.54
Liabilities    
Accounts Payable 12.33 7.06
Debt in Current Liabilities NA NA
Total Current Liabilities 23.75 18.19
Long-Term Debt NA NA
Total Liabilities 24.53 19.01
Stockholder's Equity    
Minority Interest NA NA
Preferred Stock NA NA
Common Stock 319.71 223.15
Retained Earnings -135.79 -129.92
Treasury Stock NA NA
Total Stockholders' Equity 186.47 94.53
Total Liabilities and Stockholders' Equity 211.00 113.54

Cash Flow Summary (Millions)

Categories 6/30/2018 3/31/2018
Net Cash Provided by Operating Activities 4.46 -17.57
Net Cash Provided by Investing Activities -72.26 12.54
Net Cash Provided by Financing Activities 92.35 0.13

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20159.66-19.17--
12/201611.01-33.81--
12/201751.76-10.41-0.64
Growth Rates131.48----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18488,03625.15




Report Date : 9/24/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.